Ensoma is developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system to cure diseases from within.

Nido Biosciences develops first-in-class small molecule therapeutics for the treatment of neurological diseases. We are taking a precision medicine approach against novel genetically validated targets and are advancing multiple programs.

ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

SURGE Therapeutics (The Intraoperative Immunotherapy Company™) seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed.